7831p -47.0 -0.6%
Last Trade - 11:34am
| Market Cap | £103.37bn |
| Enterprise Value | £114.81bn |
| Revenue | £18.56bn |
| Position in Universe | 11th / 1834 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
| Last Annual | December 31st, 2018 |
| Last Interim | September 30th, 2019 |
| Incorporated | June 17, 1992 |
| Public Since | September 21, 2007 |
| No. of Shareholders: | 83,588 |
| No. of Employees: | 64,400 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE4GD UK 50, FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 100 , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSE 350 , FTSE 350 Lower Yield , FTSE Global 100, FTSE 350 Pharmaceuticals & Biotechnology , FTSE 100 , FTSE Techmark All Share , , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 1,312,137,976 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 Francis Crick Avenue, CAMBRIDGE, CB2 0AA, United Kingdom |
| Web | https://www.astrazeneca.com/Home |
| Phone | +44 20 73045000 |
| Contact | Thomas Larsen (Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
